WHAT IS CLAIMED IS:

1. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (I):



(I)

or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

R_1 is H, C_{1-4} alkyl;

Q is a bond, or C_{1-4} alkyl;

A is aryl, heteroaryl optionally substituted with 0-3 substituents independently chosen from halogen, C_{1-4} alkyl, CH_2F, CHF_2, CF_3, CN, aryl, hetaryl, OCF_3, OC_{1-4}alkyl, OC_{2-5}alkylNR_4R_5, Oaryl, Ohetaryl, CO_2R_4, $CONR_4R_5$, nitro, NR_4R_5, C_{1-4} alkylNR_4R_5, NR_6C_{1-4}alkylNR_4R_5, NR_4COR_5, $NR_6CONR_4R_5$, $NR_4SO_2R_5$;

R_4, R_5 are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cycloalkyl, C_{1-4} alkyl cyclohetalkyl, aryl, hetaryl, C_{1-4}alkyl aryl, C_{1-4} alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_7;

R_6 is selected from H, C_{1-4} alkyl;

R_7 is selected from H, C_{1-4} alkyl, aryl, hetaryl, C_{1-4}alkyl aryl, C_{1-4} alkyl hetaryl;

R_2 is 0-2 substituents independently selected from halogen, C_{1-4}alkyl, OH, OC_{1-4}alkyl, CH_2F, CHF_2, CF_3, OCF_3, CN, C_{1-4}alkylNR_8R_9, OC_{1-4}alkylNR_8R_9, CO_2R_8, $CONR_8R_9$, NR_8R_9, NR_8COR_9, $NR_{10}CONR_8R_9$, $NR_8SO_2R_9$;

R_8, R_9 are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cycloalkyl, C_{1-4} alkyl cyclohetalkyl, aryl, hetaryl, C_{1-4} alkyl aryl, C_{1-4} alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{11};

R_{10} is selected from H, C_{1-4} alkyl, aryl or hetaryl;

R_{11} is selected from H, C_{1-4} alkyl, aryl, hetaryl, C_{1-4}alkyl aryl, C_{1-4} alkyl hetaryl;

Y is halogen, OH, $NR_{12}R_{13}$, $NR_{14}COR_{12}$, $NR_{14}CONR_{12}R_{13}$, $N_{14}SO_2R_{13}$;

R_{12} and R_{13} are each independently H, CH_2F, CHF_2, CF_3, CN, C_{1-4} alkyl optionally substituted with OH, OC_{1-4}alkyl or NR15R16, cycloalkyl; cyclohetalkyl, C_{1-4} alkyl cycloalkyl, C_{1-4} alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-6 membered ring optionally containing an atom selected from O, S, NR_{14};

R_{14}, R_{15} and R_{16} are each independently selected from H, C_{1-4} alkyl;

n=0-4;

W is selected from H, C_{1-4}alkyl, C_{2-6}alkenyl; where C_{1-4}alkyl or C_{2-6}alkenyl may be optionally substituted with C_{1-4}alkyl, OH, OC_{1-4}alkyl, $NR_{15}R_{16}$;

R_{15}, and R_{16} are each independently H, C_{1-4} alkyl, C_{1-4}alkyl cycloalkyl, C_{1-4} alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{17}; and

R_{17} is selected from H, C_{1-4} alkyl.

2. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (II):



(II)

or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

R_1 is H, C_{1-4} alkyl;

Q is a bond, or C_{1-4} alkyl;

A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C_{1-4} alkyl, CH_2F, CHF_2, CF_3, CN, aryl, hetaryl, OCF_3, OC_{1-4}alkyl, OC_{2-5}alkylNR_4R_5, Oaryl, Ohetaryl, CO_2R_4, $CONR_4R_5$, nitro, NR_4R_5, C_{1-4} alkylN R_4R_5, NR_6C_{1-4}alkylN R_4R_5, NR_4COR_5, NR_6CON R_4R_5, $NR_4SO_2R_5$;

R_4, R_5 are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cycloalkyl, C_{1-4} alkyl cyclohetalkyl, aryl, hetaryl, C_{1-4}alkyl aryl, C_{1-4} alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_7;

R_6 is selected from H, C_{1-4} alkyl;

R_7 is selected from H, C_{1-4} alkyl, aryl, hetaryl, C_{1-4}alkyl aryl, C_{1-4} alkyl hetaryl;

R_2 is 0-2 substituents independently selected from C_{1-4}alkyl and OC_{1-4}alkyl;

Y is CH_2OH, OC_{1-4}alkylOH, OC_{1-4}alkylR_{12}, OC_{1-4}alkyl$NR_{12}NR_{13}$, C(O)R12, CH_2R_{12}, $COOR_{12}$, $CONR_{12}R_{13}$, OCON $R_{12}R_{13}$, CH_2N $R_{12}R_{13}$, $NHCOR_{12}$, NHCON $R_{12}R_{13}$,

R_{12} and R_{13} are each independently H, C_{1-2} alkyl, $(CH_2)_3NEt_2$, $(CH_2)_2NMe_2$, $(CH_2)_5NH_2$, $(CH_2)_2OH$,



n=0-4;

W is selected from H, C_{1-4}alkyl, C_{2-6}alkenyl; where C_{1-4}alkyl or C_{2-6}alkenyl may be optionally substituted with C_{1-4}alkyl, OH, OC_{1-4}alkyl, $NR_{15}R_{16}$;

R_{15}, and R_{16} are each independently H, C_{1-4} alkyl, C_{1-4}alkyl cycloalkyl, C_{1-4} alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{17}

R_{17} is selected from H, C_{1-4} alkyl; and

wherein when Y is CH_2R_{12} then R_{12} is not H, C_{1-2}alkyl.

3. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (III):



(III)

or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

X_1, X_2, X_3, X_4 are selected from the following:

(i) X_1 and X_2 are N and X_3 and X_4 are C independently substituted with Y;

(ii) X_1 and X_4 are N and X_2 and X_3 are C independently substituted with Y;

(iii) X_1 and X_3 are N and X_2 and X_4 are C independently substituted with Y;

(iv) X_2 and X_4 are N and X_1 and X_3 are C independently substituted with Y;

(v) X_1 is N and X_2, X_3, and X_4 are C independently substituted with Y;

(vi) X_3 is N and X_1, X_2, and X_4 are C independently substituted with Y;

(vii) X_4 is N and X_1, X_2, and X_3 are C independently substituted with Y;

(viii) X_2 is N and X_1, X_3, and X_4 are C independently substituted with Y; and

(ix) X_1, X_2 and X_3 are N and X_4 is C substituted with Y;

R_1 is H, C_{1-6}alkyl, C_{1-6}alkylNR_5R_6, C_{1-6}alkylNR_5COR_6, C_{1-6}alkyl$NR_5SO_2R_6$, C_{1-6}alkylCO_2R_5, C_{1-6}alkyl$CONR_5R_6$;

R_5 and R_6 are each independently H, C_{1-4}alkyl, aryl, hetaryl, C_{1-4}alkylaryl, C_{1-4}alkylhetaryl or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_7;

R_7 is selected from H, C_{1-4}alkyl;

R_2 is selected from C_{1-6}alkylOH, OC_{2-6}alkylOH, C_{1-6}alkylNR_8R_9, OC_{2-6}alkyl$N\ R_8R_9$, C_{1-6}alkylNR_8COR_9, OC_{2-6}alkylNR_8COR_9, C_{1-6}alkylhetaryl, OC_{2-6}alkylhetaryl, $OCON\ R_8R_9$, NR_8COOR_9, $NR_{10}CONR_8R_9$, $CONR_8R_9$, NR_8COR_{12};

R_8, R_9 are each independently H, C_{1-4}alkyl, C_{1-4}alkyl$NR_{11}R_{13}$, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{14};

R_{12} is C_{2-4}alkyl, C_{1-4}alkyl$NR_{11}R_{13}$, hetaryl, cyclohetalkyl;

R_{11}, R_{13} are each independently H, C_{1-4}alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{14};

R_{14} is selected from H, C_{1-4}alkyl;

R_{10} is H, C_{1-4} alkyl;

R_3 and R_4 are each independently H, halogen, C_{1-4}alkyl, OH, OC_{1-4}alkyl, CF_3, OCF_3;

Q is a bond, or C_{1-4} alkyl;

W is selected from H, C_{1-4}alkyl, C_{2-6}alkenyl; where C_{1-4}alkyl or C_{2-6}alkenyl may be optionally substituted with C_{1-4}alkyl, OH, OC_{1-4}alkyl, $NR_{15}R_{16}$;

R_{15} and R_{16} are each independently H, C_{1-4}alkyl, C_{1-4}alkyl cycloalkyl, C_{1-4}alkyl cyclohetalkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{17};

R_{17} is selected from H, C_{1-4}alkyl;

A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C_{1-4} alkyl, CF_3, aryl, hetaryl, OCF_3, OC_{1-4}alkyl, OC_{2-5}alkyl$NR_{18}R_{19}$, Oaryl, Ohetaryl, CO_2R_{18}, $CONR_{18}R_{19}$, $NR_{18}R_{19}$, C_{1-4} alkyl$NR_{18}R_{19}$, $NR_{20}C_{1-4}$alkyl$NR_{18}R_{19}$, $NR_{18}COR_{19}$, $NR_{20}CONR_{18}R_{19}$, $NR18SO_2R_{19}$;

R_{18}, R_{19} are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cyclohetalkyl, aryl, hetaryl, C_{1-4}alkyl aryl, C_{1-4} alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{21};

R_{21} is selected from H, C_{1-4}alkyl;

R_{20} is selected from H, C_{1-4}alkyl;

Y is selected from H, C_{1-4}alkyl, OH, $NR_{22}R_{23}$; and

R_{22}, R_{23} are each independently H, C_{1-4}alkyl.

4. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (IV):



(IV)

or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

X_1, X_2, X_3, X_4 are selected from the following:

(i) X_1 and X_2 are N and X_3 and X_4 are C independently substituted with Y;

(ii) X_1 and X_4 are N and X_2 and X_3 are C independently substituted with Y;

(iii) X_1 and X_3 are N and X_2 and X_4 are C independently substituted with Y;

(iv) X_2 and X_4 are N and X_1 and X_3 are C independently substituted with Y;

(v) X_1 is N and X_2, X_3, and X_4 are C independently substituted with Y;

(vi) X_3 is N and X_1, X_2, and X_4 are C independently substituted with Y;

(vii) X_4 is N and X_1, X_2, and X_3 are C independently substituted with Y;

(viii) X_2 is N and X_1, X_3, and X_4 are C independently substituted with Y; and

(ix) X_1, X_2 and X_3 are N and X_4 is C substituted with Y;

R_1 is H, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkylNR_5R_6, where R_5 and R_6 are each independently H, $C_{1\text{-}4}$alkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_7; R_7 is selected from H, $C_{1\text{-}4}$alkyl;

R_2 is selected from $C_{1\text{-}6}$alkylOH, $OC_{2\text{-}6}$alkyl OH, $C_{1\text{-}6}$alkylNR_8R_9, $OC_{2\text{-}6}$alkyl NR_8R_9, $C_{1\text{-}6}$alkylNR_8COR_9, $OC_{2\text{-}6}$alkylNR_8COR_9, $C_{1\text{-}6}$alkylhetaryl, $OC_{2\text{-}6}$alkylhetaryl, $OCONR_8R_9$, NR_8COOR_9, $NR_{10}CONR_8R_9$, $CONR_8R_9$, NR_8COR_{12};

R_8, R_9 are each independently H, $C_{1\text{-}4}$alkyl, $C_{1\text{-}4}$alkyl$NR_{11}R_{13}$, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{14};

R_{12} is C_{2-4}alkyl, C_{1-4}alkyl$NR_{11}R_{13}$, hetaryl, cyclohetalkyl;

R_{11}, R_{13} are each independently H, C_{1-4}alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{14}; R_{14} is selected from H, C_{1-4}alkyl;

R_{10} is H, C_{1-4}alkyl;

R_3 and R_4 are each independently H, halogen, C_{1-4}alkyl, OH, OC_{1-4}alkyl, CF_3, OCF_3;

Q is CH;

W is selected from C_{1-4}alkyl, C_{2-6}alkenyl; where C_{1-4}alkyl or C_{2-6}alkenyl may be optionally substituted with C_{1-4}alkyl, OH, OC_{1-4}alkyl, $NR_{15}R_{16}$;

R_{15}, and R_{16} are each independently H, C_{1-4}alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{17};

R_{17} is selected from H, C_{1-4}alkyl;

A is aryl, hetaryl optionally substituted with 0-2 substituents independently chosen from halogen, C_{1-4}alkyl, CF_3, aryl, hetaryl, OCF_3, OC_{1-4}alkyl; OC_{2-3}alkyl$NR_{18}R_{19}$, Oaryl, Ohetaryl, CO_2R_{18}, $CONR_{18}R_{19}$, $NR_{18}R_{19}$, C_{1-4}alkyl$NR_{18}R_{19}$, $NR_{20}C_{1-4}$alkyl$NR_{18}R_{19}$, $NR_{18}COR_{19}$, $NR_{20}CONR_{18}R_{19}$, $NR_{18}SO_2R_{19}$;

R_{18}, R_{19} are each independently H, C_{1-4}alkyl, C_{1-4}alkyl cyclohetalkyl, aryl, hetaryl, C_{1-4}alkyl aryl, C_{1-4}alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{21};

R_{21} is selected from H, C_{1-4}alkyl;

R_{20} is selected from H, C_{1-4}alkyl;

Y is selected from H, C_{1-4}alkyl, $NR_{22}R_{23}$; and

R_{22}, R_{23} are each independently H, C_{1-4}alkyl.

5. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (V):



or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

X_1, X_2, X_3, X_4 are selected from the following:

(i) X_1 and X_2 are N and X_3 and X_4 are C independently substituted with Y;

(ii) X_1 and X_4 are N and X_2 and X_3 are C independently substituted with Y;

(iii) X_2 and X_4 are N and X_1 and X_3 are C independently substituted with Y;

(iv) X_1 is N and X_2, X_3, and X_4 are C independently substituted with Y;

(v) X_3 is N and X_1, X_2, and X_4 are C independently substituted with Y;

(vi) X_4 is N and X_1, X_2, and X_3 are C independently substituted with Y;

(vii) X_2 is N and X_1, X_3, and X_4 are C independently substituted with Y; and

(viii) X_1, X_2 and X_3 are N and X_4 is C substituted with Y;

R_1 is H, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$ alkylNR_5R_6, $C_{1\text{-}6}$alkylNR_5COR_6, $C_{1\text{-}6}$alkyl$NR_5SO_2R_6$, $C_{1\text{-}6}$alkylCO_2R_5, $C_{1\text{-}6}$alkyl$CONR_5R_6$;

R_5 and R_6 are each independently H, $C_{1\text{-}4}$alkyl, aryl, hetaryl, $C_{1\text{-}4}$alkylaryl, $C_{1\text{-}4}$alkylhetaryl or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_7;

R_7 is selected from H, $C_{1\text{-}4}$alkyl;

R_2 is selected from OH, $OC_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkylOH, $OC_{2\text{-}6}$alkylOH, $C_{1\text{-}6}$alkylNR_8R_9, $OC_{2\text{-}6}$alkylNR_8R_9, $C_{1\text{-}6}$alkylNR_8COR_9, $OC_{2\text{-}6}$alkylNR_8COR_9, $C_{1\text{-}6}$alkylhetaryl, $OC_{2\text{-}6}$alkylhetaryl, $OCONR_8R_9$, NR_8COOR_9, $NR_{10}CONR_8R_9$, $CONR_8R_9$, NR_8COR_{12};

R_8, R_9 are each independently H, $C_{1\text{-}4}$alkyl, $C_{1\text{-}4}$alkyl$NR_{11}R_{13}$, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{14};

R_{12} is $C_{2\text{-}4}$alkyl, $C_{1\text{-}4}$alkyl$NR_{11}R_{13}$, hetaryl, cyclohetalkyl;

R_{11}, R_{13} are each independently H, C_{1-4}alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{14};

R_{14} is selected from H, C_{1-4}alkyl;

R_{10} is H, C_{1-4} alkyl;

R_3 and R_4 are each independently H, halogen, C_{1-4}alkyl, OH, OC_{1-4}alkyl, CF_3, OCF_3;

Q is a bond, or C_{1-4}alkyl;

W is selected from H, C_{1-4}alkyl, C_{2-6}alkenyl; where C_{1-4}alkyl or C_{2-6}alkenyl may be optionally substituted with C_{1-4}alkyl, OH, OC_{1-4}alkyl, $NR_{15}R_{16}$;

R_{15}, and R_{16} are each independently H, C_{1-4}alkyl, C_{1-4}alkyl cycloalkyl, C_{1-4}alkyl cyclohetalkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{17};

R_{17} is selected from H, C_{1-4}alkyl;

A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C_{1-4} alkyl, CF_3, aryl, hetaryl, OCF_3, OC_{1-4}alkyl, OC_{2-5}alkyl$NR_{18}R_{19}$, Oaryl, Ohetaryl, CO_2R_{18}, $CONR_{18}R_{19}$, $NR_{18}R_{19}$, C_{1-4} alkyl$NR_{18}R_{19}$, $NR_{20}C_{1-4}$alkyl$NR_{18}R_{19}$, $NR_{18}COR_{19}$, $NR_{20}CONR_{18}R_{19}$, $NR_{18}SO_2R_{19}$;

R_{18}, R_{19} are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cyclohetalkyl, aryl, hetaryl, C_{1-4}alkyl aryl, C_{1-4} alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR_{21};

R_{21} is selected from H, C_{1-4} alkyl;

R_{20} is selected from H, C_{1-4} alkyl;

Y is selected from H, C_{1-4}alkyl, OH, $NR_{22}R_{23}$;

R_{22}, R_{23} are each independently H, C_{1-4} alkyl.

6. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (VI):



(VI)

or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

R'$_1$ is C_{1-4} alkyl,

R'$_2$ is independently selected from the group consisting of: OH, NHCOR'$_{12}$, and NHCONHR'$_{12}$;

R'$_{12}$ is independently selected from the group consisting of H, C_{1-4} alkyl optionally substituted with OH, OC_{1-4}alkyl or NR'$_{15}$R'$_{16}$;

R'$_{15}$ and R'$_{16}$ are each independently selected from H and C_{1-4} alkyl;

X'$_1$, X'$_2$, X'$_3$, X'$_4$ are selected from the following:

(i) X'$_1$ and X'$_2$ are N and X'$_3$ and X'$_4$ are C independently substituted with Y';

(ii) X'$_1$ and X'$_4$ are N and X'$_2$ and X'$_3$ are C independently substituted with Y';

(iii) X'$_1$ and X'$_3$ are N and X'$_2$ and X'$_4$ are C independently substituted with Y';

(iv) X'$_2$ and X'$_4$ are N and X'$_1$ and X'$_3$ are C independently substituted with Y';

Y' is selected from H, OH, C_{1-4}alkyl, and OC_{1-4}alkyl;

X'$_5$ is selected from N and C, and

when X'$_5$ is C, R'$_6$ is selected from the group H, halogen, C_{1-4} alkyl, OC_{1-4}alkyl, CF_3, and OCF_3:

R'$_5$ is selected from the group C_{1-4} alkyl, OC_{1-4}alkyl, CF_3, and OCF_3; and

R'$_7$ is selected from the group H, halogen, C_{1-4} alkyl, OC_{1-4}alkyl, CF_3, and OCF_3.

7. The method according to claim 6, wherein the compound of the general formula (VI) selected from the group consisting of:


;


;


;


;


;


;


;


;


;


;


;


;


;


;


;


;


;


;




;


;


;


;

and


;

or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof.

8. The method of claim 7, wherein the compound is



or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof.

9. The method of any of claims 1-8, wherein the liver cancer is selected from the group consisting of: hepatocellular carcinoma (HCC), fibrolamellar HCC, bile duct cancer, angiosarcoma, and secondary liver cancer.

10. The method of any of claims 1-8, wherein the liver cancer is HCC.

11. The method of any of claims 1-10, wherein the subject is a human.

12. The method of any of claims 1-10, further comprising monitoring the subject for change(s) in sign(s) and/or symptom(s) of liver cancer responsive to administering the compound.

13. The method of any of claims 1-10, wherein the compound is administered as a monotherapy.

14. The method of any of claims 1-10, further comprising administering a second therapeutic agent to the subject.

15. The method of any of claims 1-10, wherein the compound is administered intravenously, subcutaneously, or orally.

16. Use of a compound of the general formulas (I), (II), (III), (IV), (V), or (VI) for the treatment of liver cancer.

17. The use according to claim 16, wherein the compound is selected from


;


;


;


;


;


;


;


;


;


;


;


;


;

;

;

;

;

;


;

;

;

;
and

or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof.

18. The use according to claim 17, wherein the compound is



(24)

or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof.

19. The use according to any of claims 16-18, wherein the liver cancer is selected from the group consisting of: hepatocellular carcinoma (HCC), fibrolamellar HCC, bile duct cancer, angiosarcoma, and secondary liver cancer.

20. The use according to any of claims 16-18, wherein the liver cancer is HCC.

21. The use according to any of claims 16-20, wherein the treatment is applied to a human.